Sage Journals: Discover world-class research

Abstract

Adenosine 5′-triphosphate acts as an extracellular signalling molecule (purinergic signalling), as well as an intracellular energy source. Adenosine 5′-triphosphate receptors have been cloned and characterised. P1 receptors are selective for adenosine, a breakdown product of adenosine 5′-triphosphate after degradation by ectonucleotidases. Four subtypes are recognised, A₁, A_2A, A_2B and A₃ receptors. P2 receptors are activated by purine and by pyrimidine nucleotides. P2X receptors are ligand-gated ion channel receptors (seven subunits (P2X1-7)), which form trimers as both homomultimers and heteromultimers. P2Y receptors are G protein-coupled receptors (eight subtypes (P2Y_{1/2/4/6/11/12/13/14})). There is both purinergic short-term signalling and long-term (trophic) signalling. The cloning of P2X-like receptors in primitive invertebrates suggests that adenosine 5′-triphosphate is an early evolutionary extracellular signalling molecule. Selective purinoceptor agonists and antagonists with therapeutic potential have been developed for a wide range of diseases, including thrombosis and stroke, dry eye, atherosclerosis, kidney failure, osteoporosis, bladder incontinence, colitis, neurodegenerative diseases and cancer.

Keywords

Adenosine 5′-triphosphate adenosine P1 receptor P2X receptor P2Y receptor

Introduction

The potent actions of adenine compounds were first described by Drury and Szent-Györgyi in 1929. Years later, adenosine 5′-triphosphate (ATP) was proposed as the transmitter responsible for non-adrenergic, non-cholinergic transmission in the gut and bladder, and the term ‘purinergic’ was introduced by Burnstock in 1972. Early resistance to this concept was understandable since ATP was recognised first for its intracellular roles in many biochemical processes and the intuitive feeling was that such a ubiquitous and simple compound was unlikely to be utilised as an extracellular messenger. However, enzymes involved in the breakdown of extracellular ATP had already been described by the mid-1990s (see Yegutkin, 2008).

The concept of purinergic neurotransmission and the potent actions of extracellular ATP on many different cell types implied that there were purinergic membrane receptors. Purinergic receptors were described first in 1976 (Burnstock, 1976). Two years later, a basis for distinguishing two families of purinoceptors was proposed, identifying P1 and P2 receptors (for adenosine and ATP/adenosine 5′-diphosphate (ADP), respectively; Burnstock, 1978). Soon after, two subtypes of the P1 (adenosine) receptor were recognised (Londos et al., 1980; Van Calker et al., 1979). In 1985, a pharmacological basis for distinguishing two subtypes of P2 receptor (P2X and P2Y) was proposed (Burnstock and Kennedy, 1985). In the early 1990s, P1 (adenosine) receptors were cloned and characterised, and four subtypes were recognised (see Fredholm et al., 2001). In 1993, the first G protein-coupled P2Y receptors were cloned (Lustig et al., 1993; Webb et al., 1993) and a year later two P2X ligand-gated ion channel receptors (Brake et al., 1994; Valera et al., 1994). In 1994, it was proposed, on the basis of molecular structure and transduction mechanisms, that purinoceptors should belong to these two major families (Abbracchio and Burnstock, 1994). Currently, seven P2X receptor subtypes and eight P2Y receptor subtypes are recognised, including receptors that are sensitive to pyrimidines as well as purines (Abbracchio et al., 2006; North, 2002; Ralevic and Burnstock, 1998).

Purinergic signalling appears to be a primitive evolutionary system (see Verkhratsky and Burnstock, 2014). Many non-neuronal as well as neuronal mechanisms, including immune responses, exocrine and endocrine secretion, inflammation, pain, platelet aggregation and endothelial-mediated vasodilatation, involve purinergic signalling in mammals (Burnstock, 2006; Burnstock and Knight, 2004). Cell proliferation, differentiation and death that occur in development and regeneration are also mediated by purinergic receptors (Abbracchio and Burnstock, 1998; Burnstock and Verkhratsky, 2010). Reviews describe the history of the development of purinergic signalling and discuss future developments (Burnstock, 2012, 2014).

P1 receptors

Complementary DNAs encoding for two P1 receptor subtypes (A₁ and A₂) were isolated in 1989 (Libert et al., 1989). Soon after, the A₃ subtype was identified (Zhou et al., 1992). Four different P1 receptor subtypes, A₁, A_2A, A_2B and A₃, were cloned and characterised in the early 1990s (see Fredholm et al., 2001). Polymorphisms have been observed in the A₁ and the A_2A receptors (Kumral et al., 2012). P1 receptors couple to adenylate cyclase; A₁ and A₃ are negatively coupled to adenylate cyclase, while A_2A and A_2B are positively coupled to adenylate cyclase (Reshkin et al., 2000). P1 subtype-selective agonists and antagonists have been identified (see Table 1). P1 receptor subtypes mediate diverse physiological effects, including modulation of cardiovascular, immune and central nervous system (CNS) activities (Ledent et al., 1997; Sun et al., 2001).

Table 1.

Characteristics of purine-mediated receptors.

Receptor		Main distribution	Agonists	Antagonists	Transduction mechanisms
P1 (Ado)	A₁	Brain, spinal cord, testis, heart, autonomic nerve terminals	CCPA > R-PIA = S-ENBA; CVT-510; GR792362′-MeCCPA, SDZ WAG 994, INO-8875, MRS 5474	DPCPX, N-0840, MRS1754, WRC-0571, PSB36, SLV320, CGS 16943, PQ-69	G_i/G_o ↓cAMP
	A_2A	Brain, heart, lungs, spleen	HENECA > CGS 21680 = CVT-3146; ATL-146e; Regadenoson	KF17837, SCH58261, ZM241385, KW 6002	G_S ↑cAMP
	A_2B	Large intestine, bladder	Bay60-6583, NECA	PSB603, MRE-2029-F20, MRS1754, PSB0788 MRS1706, PSB1115, Alloxazine, GS-6201	G_S ↑cAMP
	A₃	Lung, liver, brain, testis, heart	IB-MECA > MRS5698 > MRS5168 > 2-Cl-IB-MECA; DBXRM; VT160; HEMADO	MRS1220, L-268605, MRS1191, MRS1523(rat), VUF8504, VUF5574, MRS1334(human), PSB10	G_i/G_o, G_q/G₁₁, ↓cAMP, PLC-β activation
P2X	P2X1	Smooth muscle, platelets, cerebellum, dorsal horn spinal neurons	BzATP > ATP = 2-MeSATP ⩾ α,β-meATP = L-β,γ-meATP (rapid desensitisation); PAPET-ATP	NF864 > NF449 > IP₅I ⩾ TNP-ATP > RO 0437626 > NF279, NF023, RO1, MRS2159	Intrinsic cation channel (Ca²⁺ and Na⁺)
	P2X2	Smooth muscle, CNS, retina, chromaffin cells, autonomic and sensory ganglia, pancreas	ATP ⩾ ATPγS⩾2-MeSATP >> α,β-meATP (pH + zinc sensitive); β,γ-CF₂ATP	PSB-1011 > RB2, isoPPADS > PPADS > Suramin, NF770, NF778, Aminoglycoside	Intrinsic ion channel (particularly Ca²⁺)
	P2X3	Sensory neurones, NTS, some sympathetic neurons	2-MeSATP ⩾ ATP ⩾ Ap₄A ⩾ α,β-meATP (rapid desensitisation); PAPET-ATP; BzATP	TNP-ATP, AF353, A317491, RO3, isoPPADS > NF110 > PPADS, Ip₅I, phenol red, RN-1838, Spinorphin	Intrinsic cation channel
	P2X4	CNS, testis, colon, endothelial cells, microglia	ATP >> α,β-meATP >> CTP, 2-MeSATP Ivermectin potentiation	5-BDBD >> TNP-ATP, PPADS > BBG, Paroxetine, phenolphthalein, CO donor (CORM 2), 5MPTP	Intrinsic ion channel (especially Ca²⁺)
	P2X5	Proliferating cells in skin, gut, bladder, thymus, spinal cord, heart, adrenal medulla	ATP = 2-MeSATP = ATPγS >> α,β-meATP > AP₄A	BBG > PPADS, Suramin	Intrinsic ion channel
	P2X6	CNS, motor neurons in spinal cord	Only functions as a heteromultimer	–	Intrinsic ion channel
	P2X7	Immune cells including dendritic cells (mast cells, macrophages), pancreas, skin, microglia	BzATP > ATP ⩾ 2-MeSATP >> α,β-meATP (clemastine potentiates)	KN62, BBG, KN04, MRS2427, O-ATP, RN-6189, Perazine, AZ10606120, A740003, A-438079, A-804598, GSK-1370319, Comp 31 (GSK), AZD-9056, CE-224,535, JNJ-47965567, JNJ-42253432 (penetrates BBB), decavanadate, AZ11657312	Intrinsic cation channel and a large pore with prolonged activation
P2Y	P2Y₁	Epithelial and endothelial cells, platelets, immune cells, osteoclasts, brain	MRS2365 > 2-MeSADP = Ap₅(γB) >> ADPβS > ATP > 2-MeSATP = ADP	MRS2500 > MRS2279 > MRS2179, PIT, A3P5P	G_q/G₁₁; PLC-β activation
	P2Y₂	Immune cells, epithelial and endothelial cells, kidney tubules, osteoblasts	2-thio-UTP > UTP, MRS2698 ⩾ ATP, INS 365 > INS 37217, UTPγS > Ap₄A > MRS 2768, Up₄-phenyl ester	AR-C126313 > Suramin > RB2, PSB-716, MRS2576, PSB-0402, AR-C118925	G_q/G₁₁ and possibly G_i/G_o; PLC-β activation
	P2Y₄	Endothelial cells, placenta, spleen, thymus	2′-azido-dUTP > UTPγS, UTP ⩾ ATP ⩾ Ap₄A Up₄U MRS4062	ATP (human) > Reactive Blue 2 > Suramin, MRS2577, PPADS	G_q/G₁₁ and possibly G_i; PLC-β activation
	P2Y₆	Airway and intestinal epithelial cells, placenta, T cells, thymus, microglia (activated)	MRS2693 > UDPβS, PSB0474 > INS48823, Up₃U, 3-phenacyl-UDP >> UDP > UTP >> ATP, α,β-meUDP, MRS2957, MRS4129, 5-OMe-UDP αB	MRS2578 > Reactive Blue 2, PPADS, MRS2567, MRS2575 (human)	G_q/G₁₁; PLC-β activation
	P2Y₁₁	Spleen, intestine, granulocytes	ATPγS > AR-C67085MX > BzATP ⩾ ATP, NF546, NAD⁺, NAADP⁺, Sp-2-propylthio-ATP-α-B	NF157 > Suramin > RB2, 5′-AMPS, NF340, AMP-α-5	G_q/G₁₁ and G_S; PLC-β activation
	P2Y₁₂	Platelets, glial cells	2-MeSADP ⩾ ADP > ATP, ADP-β-S	AR-C69931MX > AZD6140 (Ticagrelor), INS50589 > RB2 > 2-MeSAMP AR-C66096, CT50547, PSB-0413, Carba-nucleosides, MRS2395, AR-C67085, [³H]PSB-0413; clopidogrel, AZD1283; ACT-246475	Gα_I; inhibition of adenylate cyclase
	P2Y₁₃	Spleen, brain, lymph nodes, bone marrow, erythrocytes	ADP = 2-MeSADP > 2-MeSATP, ATP	AR-C69931MX > AR-C67085 > MRS2211, 2-MeSAMP	G_i/G_o
	P2Y₁₄ GPR17	Placenta, adipose tissue, stomach, intestine, discrete brain regions, mast cellsOligodendrocytes	MRS2690 > UDP > UDP glucose ⩾ UDP-galactose, UDP-glucosamine, MRS2905Uracil nucleotides/cysteinyl-leukotrienes, MDL29,951	PPTNPZB01415033	G_q/G₁₁ G_i, adenylate cyclase inhibition

Source: Updated from Burnstock (2003), with permission from Elsevier.

A3P5P: adenosine-3′-5′-bisphosphate; ADP: adenosine 5′-diphosphte; ADPβS: adenosine-5′-(β-thio)-diphosphate; 5′-AMPS: 5′-O-thiomnophosphate; Ap₄A: diadenosine tetraphosphate; Ap5(γβ): adenosine pentaphosphate (βγ); ATPγS: adenosine-5′-(γ-thio)-triphosphate; ATP: adenosine 5′-triphosphte; ATPγS: adenosine-5′-(γ-thio)-triphosphate; BBG: brilliant blue green; 5-BDBD: 5-(3-bromophenyl)-1,3-dihydro-2H-benzofuro[3,2-e]-1,4-diazepin-2-one; BzATP: 2′(3′)-O-(4-benzoylbenzoyl) adenosine 5′-triphosphate; β,γ-CF2ATP: α,β-difluoromethylene-ATP; cAMP: cyclic AMP; CCPA: chlorocyclopentyl adenosine; 2-Cl-IB-MECA: 2-chloro-N6-(3-iodobenzyl)-9-[5-(methylcarbamoyl)-β-d-ribofuranosyl]adenine; CNS: central nervous system; CORM 2: carbon monoxide donor 2; CTP: cytosine triphosphate; DBXRM: 1,3-dibutylxanthine 7-riboside 5′-N-methylcarboxamide; DPCPX: 1,3-dipropyl-8-cyclopentylxanthine; GTP: guanosine-5′-triphosphate; HEMADO: 2-(1-Hexynyl)-N-methyl adenosine; HENECA: 2-hexynyladenosine-59-N-ethylcarboxamide; IB-MECA: N6-(3-Iodobenzyl)-9-[5-(methylcarbamoyl)-β-d-ribofuranosyl]adenine; IP₅I: di-inosine pentaphosphate; isoPPADS: iso-pyridoxalphosphate-6-azophenyl-2′,4′-disulfonic acid; L-α,β-meATP: L-α,β-methylene ATP; L-β,γ-meATP: L-β,γ-methylene ATP; 2′-MeCCPA: 2-chloro-N-cyclopentyl-2′-methyladenosine; 2-MeSADP: 2-methylthio ADP; 2-MeSAMP: 2-methylthio AMP; 2-MeSATP: 2-methylthio ATP; α,β-meUDP: α,β-methylene UDP; NAADP⁺: nicotinic acid adenine dinucleotide phosphate; NAD⁺: nicotinamide adenine dinucleotide; NECA: 5′-N-ethylcarboxamido adenosine; NTS: nucleus tractus solitarius; oATP: oxidised ATP; PAPET: 2-[2-(4-aminophenyl)ethylthio]adenosine-5′-triphosphate; PIT: 2,2′-pyridylisatogen tosylate; PLC: phospholipase C; PPADS: pyridoxalphosphate-6-azophenyl-2′,4′-disulfonic acid; RB2: reactive blue 2; R-PIA: R-phenylisopropyladenosine; S(–)-ENBA: (2S)-N6-[2-endo-Norbornyl]adenosine; 2-thio-UTP: 2-thio-uridine 5′-triphosphate; TNP-ATP: 2′(3′)-O-(2,4,6-trinitrophenyl) ATP; UDP: uridine 5′-diphosphate; UDPβS: uridine 5′-O-thiodiphosphate; Up₃U: diuridine triphosphate; Up4-phenyl ester: uridine tetraphosphate phenyl ester; Up₄U: diuridine tetraphosphate; UTP: uridine 5′-triphosphate; UTPγS: uridine 5′-O-3-thiotriphosphate.

P2X receptor subtype agonist potencies are based on rat preparations, while P1 and P2Y receptor subtype agonist potencies are based on human preparations (=, equal potency; >, greater potency; ⩾, greater than or equal potency).

P2X receptors

P2X1-7 receptors show a subunit topology of intracellular N- and C- termini possessing consensus binding motifs for protein kinases and two transmembrane-spanning regions (TM1 and TM2). TM1 is involved with channel gating and TM2 lining the ion pore. There is a large extracellular loop, with 10 conserved cysteine residues (see Alves et al., 2014; North, 2002; Rokic and Stojilkovic, 2013). The stoichiometry of P2X1-7 receptors involves three subunits, which form a stretched trimer or a hexamer of conjoined trimers (Nicke et al., 1998; North, 2002; Stelmashenko et al., 2012). Heteromultimers as well as homomultimers are involved in forming the trimer ion pore (Nicke et al., 1998), including P2X2/3, P2X1/2, P2X1/5, P2X2/6, P2X4/6 and P2X1/4 receptors. Advances have been made by the use of knockout mice for P2X1, P2X2, P2X3, P2X4 and P2X7 receptors and transgenic mice that overexpress the P2X1 receptor. The association of various diseases with P2X receptor polymorphisms has been described (see Caseley et al., 2014).

P2X receptor subtypes

A complementary DNA (cDNA) encoding the P2X1 receptor was made from rat vas deferens (Valera et al., 1994). The agonist actions of ATP by α,β-methylene ATP (α,β-meATP) distinguish P2X1 and P2X3 receptors from the other homomeric forms. Several antagonists have been recognised to be selective for P2X1 receptors (see Table 1). Adenoviral expression of a P2X1 receptor-green fluorescent protein construct shows the receptor to be localised in clusters in vas deferens, with larger clusters apposing nerve varicosities (Burnstock, 2007).

Rat P2X2 receptor cDNA was isolated from PC12 cells (Brake et al., 1994) and human receptor cDNA from pituitary gland (Lynch et al., 1999). No agonists are currently known at present that are selective for P2X2 receptors. However, protons and low concentrations of zinc and copper potentiate P2X2 receptors. Antagonists for P2X2 receptors are shown in Table 1. The P2X2 receptor is non-desensitising, compared with the P2X1 and P2X3 receptors.

P2X1/2 heteromultimer receptors have been described in de-folliculated Xenopus oocytes (Brown et al., 2002; Calvert and Evans, 2004). pH sensitivity is characteristic of heteromeric P2X1/2 ion channels.

P2X3 receptor subunit cDNAs were taken from rat dorsal root ganglion cDNA libraries (Chen et al., 1995; Lewis et al., 1995), from a human heart cDNA library (Garcia-Guzman et al., 1997) and a zebrafish library (Egan et al., 2000). The antagonist NF023 is about 20 times less effective at P2X3 compared to P2X1 receptors (see Table 1). P2X3 receptors are prominently expressed on sensory neurons, including nociceptive nerve endings (Burnstock, 2003).

P2X2/3 heteromer receptors have been described (Lewis et al., 1995; Spelta et al., 2003). They exhibit a sustained current elicited by α,β-meATP. However, like homomeric P2X2 receptors, they are potentiated by low pH and, in common with the homomeric P2X3 receptor, they are very sensitive to block by 2′(3′)-O-(2,4,6-trinitrophenyl) ATP. P2X2/3 receptors are expressed by subpopulations of sensory neurons, sympathetic ganglion cells and brain neurons.

cDNAs for rat P2X4 receptors were isolated from both superior cervical ganglion (SCG) and brain (Bo et al., 1995; Buell et al., 1996). cDNAs for human, mouse, chick and Xenopus have also been isolated. P2X4 receptors are activated by ATP, but not by α,β-meATP. A useful distinguishing feature of ATP-evoked currents at P2X4 receptors is their potentiation by ivermectin. Unusual among the P2X receptors, the rat P2X4 receptor shows relative insensitivity to blockade by the conventional non-selective antagonists suramin and pyridoxalphosphate-6-azophenyl-2′,4′-disulfonic acid (PPADS). Carbamazepine derivatives have been claimed to be potent P2X4 receptor antagonists (Tian et al., 2014; see Table 1). Currents evoked by ATP at the mouse P2X4 receptor are increased by PPADS and suramin, probably because they are also ectonucleotidase inhibitors (Burnstock, 2003).

P2X1/4 heteromeric receptors were shown to have kinetic properties resembling homomeric P2X4 receptors and a pharmacological profile similar to homomeric P2X1 receptors (Nicke et al., 2005). An important advance was made when the crystal structure of the P2X4 receptor was described (Kawate et al., 2009; Figure 1).

Figure 1.

The architecture of the P2X4 receptor. Stereoview of the homotrimeric ΔzfP2X4 structure viewed parallel to the membrane. Each subunit is depicted in a different colour. N-acetylglucosamine (NAG) and glycosylated asparagine residues are shown in stick representation. The grey bars suggest the boundaries of the outer (out) and inner (in) leaflets of the membrane bilayer.

P2X5 receptor cDNA was first isolated from rat coeliac ganglion and heart (Burnstock, 2003; Garcia-Guzman et al., 1996). It was also cloned from embryonic chick skeletal muscle (Bo et al., 2000) and a bullfrog P2X5 receptor from larval skin. Human P2X5 receptor cDNAs are missing exon 10 (hP2X_5a) or exons 3 and 10 (P2X_5b) (Roberts et al., 2006; Stojilkovic et al., 2005). Currents elicited by ATP in cells expressing the rat P2X5 receptor are of small amplitude, compared with the currents observed with P2X1, P2X2, P2X3 or P2X4 receptors. P2X5 mRNA is highly expressed in developing skeletal muscle (Burnstock, 2003).

The P2X1/5 heteromer is characterised by a sustained current evoked by α,β-meATP, which does not occur for either of the homomers when expressed separately (Burnstock, 2007; Surprenant et al., 2000). Cells expressing P2X1/5 receptors are more sensitive to ATP than those with homomeric receptors. P2X2/5 heteromeric receptors have also been recognised (Compan et al., 2012).

The rat P2X6 receptor was cloned from SCG (Burnstock, 2007) and rat brain (Soto et al., 1996). The human equivalent was isolated from peripheral lymphocytes and was abundantly expressed in human and mouse skeletal muscle. The P2X6 subunit is only functionally expressed as a heteromultimer.

Heteromeric P2X2/6 receptors were expressed in HEK293 cells (Torres et al., 1999). The most convincing difference in oocytes expressing P2X2/6 receptors compared to those expressing only P2X2 receptors is that at pH 6.5 the inhibition of the current by suramin is biphasic (King et al., 2000). P2X2/6 receptors are expressed particularly by respiratory neurons in the brain stem.

P2X4/6 heteromeric receptors were described in oocytes (Khakh et al., 1999). The P2X4/6 heteromer differs only in minor respects from that of P2X4 homomers. They are prominently expressed in adult trigeminal mesencephalic nucleus and in hippocampal CA1 neurons (North, 2002).

A chimeric cDNA encoding the rat P2X7 receptor was first isolated from SCG and medial habenula. Full-length cDNAs were later isolated from a rat brain cDNA library (Surprenant et al., 1996). The unique feature of the P2X7 receptor is that in addition to the usual rapid opening of the cation-selective ion channel, with prolonged exposure to high concentrations of ATP it undergoes a channel to pore conversion to allow the passage of large dye molecules such as ethidium and YO-PRO-1. This often leads to apoptotic cell death. 2′,3′-O-(benzoyl-4-benzoyl)-ATP (BzATP) is a potent, although not selective, agonist at the P2X7 receptor. After continuous application of BzATP (30 µM) for about 30 s, the plasma membrane develops large blebs. Blebs are usually preceded by the shedding of smaller vesicles (<1 µm diameter) that release inflammatory cytokines. A number of potent antagonists have been developed (see Table 1).

P2Y receptors

P2Y₁ and P2Y₂ receptors were cloned in 1993 (Lustig et al., 1993; Webb et al., 1993). Since then several other subtypes have been isolated by homology cloning. The G_i-coupled ADP receptor (P2Y₁₂) of platelets was isolated by expression cloning in 2001 (Hollopeter et al., 2001). P2Y₁₃ and P2Y₁₄ receptors were characterised during a study of orphan receptors (Chambers et al., 2000; Communi et al., 2001a). At present, there are eight recognised human P2Y receptors: P2Y₁, P2Y₂, P2Y₄, P2Y₆, P2Y₁₁, P2Y₁₂, P2Y₁₃ and P2Y₁₄ (Abbracchio et al., 2003, 2006; see Table 1). The missing numbers represent either non-mammalian orthologs or receptors which have no functional evidence of responsiveness to nucleotides. A p2y8 receptor was cloned from the frog embryo, which was shown to be involved in the development of the neural plate (Bogdanov et al., 1997). A P2Y-like receptor, GPR17, has been described (Parravicini et al., 2008). Two distinct P2Y receptor subgroups characterised by a relatively high level of sequence divergence have been identified (Abbracchio et al., 2006). The first subgroup includes P2Y_1,2,4,6,11 and the second subgroup includes the P2Y_12,13,14 subtypes (see Figure 2). For some of the P2Y receptor subtypes, potent and selective synthetic agonists and antagonists have been identified (see Table 1). Activation of several P2Y receptors is associated with the stimulation of mitogen-activated protein kinase (MAPK; Abbracchio et al., 2006). Ion channel couplings of P2Y receptors are primarily of importance in neurons, but they have been detected in various other tissues, including cardiac muscle cells (Abbracchio et al., 2006; Vassort, 2001). Polymorphisms of P2Y₁, P2Y₂ and P2Y₁₂ receptors have been identified associated with various diseases (Läer et al., 2013; Lev et al., 2007; Wesselius et al., 2013). There is dimerisation involving P2Y receptors with non-P2Y receptors, for example, rat P2Y₁ and adenosine A₁ receptors in neurons, in rat cortex, hippocampus and cerebellum (Yoshioka et al., 2002). Functional P2Y₁ and P2Y₂ receptors, co-localised at the neuromuscular junctions with nicotinic acetylcholine (ACh) receptors, have been reported in mammalian, chicken and amphibian muscles.

Figure 2.

(a) Dendrogram to show relatedness of 29 P2X receptor subunits. Full-length amino acid sequences were aligned with Clustal W using default parameters. The dendrogram was constructed with TreeView. h, human (Homo sapiens); r, rat (Rattus norvegicus); m, mouse (Mus musculus); gp, guinea pig (Cavia porcellus); c, chicken (Gallus gallus); zf, zebrafish (Danio rerio); bf, bullfrog (Rana catesbeiana); x, claw-toed frog (Xenopus laevis); f, fugu (Takifugu rubripes). The ellipses indicate the apparent clustering by relatedness into subfamilies. Source: Reproduced from North (2002), with permission from the American Physiological Society. (b) A phylogenetic tree (dendrogram) showing the relationships among the current members of the P2Y receptor family (human P2Y₁, P2Y₂, P2Y₄, P2Y₆, P2Y₁₁, P2Y₁₂ and P2Y₁₃ receptors) and the human UDP-glucose receptor (here indicated as the P2Y₁₄ receptor). The P2Y receptors can be divided into two subgroups shown with green and lilac backgrounds. Sequences were aligned using CLUSTALX and the tree was built using the TREEVIEW software. Source: Reproduced from Abbracchio et al. (2003), with permission from Elsevier.

P2Y receptor subtypes

P2Y₁ receptors have been cloned and characterised in human, rat, mouse, cow, chick, turkey and Xenopus tissues. ADP is a more potent agonist than ATP and 2-methylthio ADP is even more potent. The most effective antagonists to display selectivity for the P2Y₁ receptor at present are MRS2179, MRS2279 and MRS2500 (see Table 1). P2Y₁ mRNA is high in different regions of the human brain, prostate gland and placenta (Burnstock and Knight, 2004; Léon et al., 1996). In post-mortem brain sections from Alzheimer’s disease patients, the P2Y₁-like immunoreactivity in the hippocampus and entorhinal cortex was localised to neurofibrillary tangles, neuritic plaques and neuropil threads (Moore et al., 2000).

P2Y₂ receptors have been cloned and characterised from human, rat, mouse, canine and porcine cells or tissues (Shen et al., 2004). P2Y₂ receptors are activated by equivalent concentrations of ATP and UTP. The γ-thiophosphate, UTPγS and INS 37217 are potent hydrolysis-resistant agonists of P2Y₂ receptors (Abbracchio et al., 2006). Current P2Y₂ receptor antagonists are shown in Table 1. Expression of P2Y₂ receptor mRNA has been described in many tissues (Burnstock and Knight, 2004). P2Y₂ receptor expression in smooth muscle cells is up-regulated by inflammatory agents, including interleukin-1β, interferon-γ and tumour necrosis factor-α (Hou et al., 2000). In epithelial cells, P2Y₂ receptor activation increases Cl⁻ secretion and inhibits Na⁺ absorption (Kellerman et al., 2002). A P2Y₂ receptor knockout mouse has been described that is defective in nucleotide-stimulated ion secretion in airway epithelial cells (Cressman et al., 1999). P2Y₂ receptors inhibit bone formation by osteoblasts (Hoebertz et al., 2002) and N-type calcium currents in neurons (Brown et al., 2000).

P2Y₄ receptors have been cloned and characterised from human, rat and mouse. UTP is the most potent activator of the human P2Y₄ receptor (Communi et al., 2004). However, the recombinant rat and mouse P2Y₄ receptors are activated equipotently by ATP and UTP (Bogdanov et al., 1998). Reactive Blue 2 blocks rat P2Y₄ receptors, but only partially blocks human P2Y₄ receptors. P2Y₄ mRNA and protein was most abundant in the intestine of both mouse and humans, but has also been described in other organs (Burnstock and Knight, 2004). P2Y₄-null mice show normal behaviour, growth and reproduction; however, the chloride secretory response to apical UTP and ATP of the jejunal epithelium was abolished (Robaye et al., 2003).

P2Y₆ receptors are selective for UDP in mouse, rat and human (Lazarowski et al., 2001). Selective agonists and antagonists are described in Table 1. A wide tissue distribution of P2Y₆ mRNA and protein has been reported, and the highest expression was in spleen, intestine, liver, brain and pituitary (Burnstock and Knight, 2004).

The human P2Y₁₁ receptor has a unique profile (Abbracchio et al., 2006). The hP2Y₁₁ receptor gene differs from other P2Y receptor subtype genes having the presence of a 1.9-kb intron in the coding sequence that separates an exon encoding the first 6 amino acid residues from a second exon encoding the remaining part of the protein (Communi et al., 2001b).

P2Y₁₂ receptors have been identified and characterised in human, rat and mouse (Abbracchio et al., 2006). ADP is the agonist of this receptor. The P2Y₁₂ receptor is highly expressed in platelets where it is the molecular target of antiplatelet drugs, clopidogrel and ticagrelor (Savi and Herbert, 2005). The P2Y₁₂ receptor is also expressed in sub-regions of the brain, glial cells, brain capillary endothelial cells, smooth muscle cells and chromaffin cells (Burnstock and Knight, 2004). P2Y₁₃ receptors have been identified and characterised in human, mouse and rat (Abbracchio et al., 2006). Naturally occurring agonists of the P2Y₁₃ receptor are ADP and di-adenosine triphosphate. Selective antagonists of the human P2Y₁₃ receptor are shown in Table 1. The P2Y₁₃ receptor is expressed in spleen, placenta, liver, heart, bone marrow, monocytes, T cells, lung and various regions of the brain (Fumagalli et al., 2004).

The P2Y₁₄ receptor is 47% identical to the P2Y₁₂ and P2Y₁₃ receptors. The gene for this receptor is in human chromosome 3q24-3q25 (Abbracchio et al., 2003). The P2Y₁₄ receptor is activated by UDP-glucose and is coupled to the G_i/o family of G proteins (Harden, 2004). P2Y₁₄ mRNA is distributed in many systems in the human body. Chemoattractant and neuroimmune functions have been claimed for the P2Y₁₄ receptor.

Physiology of purinergic signalling

Early studies were focused largely on short-term purinergic signalling in neurotransmission, neuromodulation, secretion, chemoattraction and acute inflammation, but there is increasing interest in long-term (trophic) signalling involving cell proliferation, differentiation, motility and death in development, regeneration, wound healing, restenosis, epithelial cell turnover, cancer and ageing (Abbracchio and Burnstock, 1998; Burnstock and Verkhratsky, 2010). In blood vessels, there is dual purinergic short-term control of vascular tone by ATP (Burnstock, 2002): ATP released as a cotransmitter from perivascular sympathetic nerves activate P2X receptors resulting in contraction of smooth muscle; ATP released from endothelial cells during changes in blood flow (shear stress) and hypoxia acts on P2X and P2Y receptors on endothelial cells, resulting in production of nitric oxide and relaxation. There is also long-term control of cell proliferation and differentiation, migration and death involved neovascularisation, restenosis following angioplasty and atherosclerosis (Erlinge and Burnstock, 2008). Purinergic signalling is involved in development, ageing and regeneration (Burnstock, 2007). Purinergic receptors are expressed on stem cells (Burnstock and Ulrich, 2011; Delic and Zimmermann, 2010; Trujillo et al., 2009). Many cell types release ATP physiologically in response to gentle mechanical distortion, hypoxia or some agents (Bodin and Burnstock, 2001). The mechanism of ATP transport includes, in addition to vesicular release, ABC transporters, connexin or pannexin hemi-channels, maxi-ion channels and even P2X7 receptors (Burnstock, 2007; Lazarowski et al., 2011). Extracellular breakdown of released ATP is by ectonucleotidases, including E-NTPDases, E-NPPS, alkaline phosphatase and ecto-5′-nucleotidose (Yegutkin, 2008; Zimmermann et al., 2007). P1 and P2 receptors are involved in neurotransmission and neuromodulation in the CNS, and in normal behaviour, including memory, feeding, locomotion and cognition (Burnstock et al., 2011).

Purinergic pathophysiology and therapeutic potential

ATP was shown early to be a major cotransmitter with ACh in parasympathetic nerves mediating contraction of the urinary bladder of rodents (Burnstock et al., 1978). However, in healthy human bladder, the role of ATP as a cotransmitter is minor, but under pathological conditions, such as interstitial cystitis, outflow obstruction and most types of neurogenic bladder, the purinergic component is increased to about 40% (Burnstock, 2001, 2006). There is also a significantly greater cotransmitter role for ATP in sympathetic nerves in spontaneously hypertensive rats (Vidal et al., 1986). P2X3 receptors are located on small nociceptive sensory nerves and are involved in the initiation of pain (Bradbury et al., 1998; Burnstock, 1996, 2013; Chen et al., 1995). There are peripheral extensions of the sensory nerves in skin, tongue and visceral organs and central projections to inner lamina 2 of the spinal cord. A hypothesis describing purinergic mechanosensory transduction and pain in visceral organs was published in 1999 (Burnstock, 1999). It was proposed that ATP, released from urothelial/epithelial cells during distension, acts on P2X3 and P2X2/3 receptors on subepithelial sensory nerve endings to send nociceptive messages via sensory ganglia to the pain centres in the brain (Burnstock, 1999). Supporting evidence has been reported in the bladder (Vlaskovska et al., 2001), ureter (Rong and Burnstock, 2004) and gut (Wynn and Burnstock, 2006). Purinergic mechanosensory transduction via low threshold fibres is also involved in urine voiding (Cockayne et al., 2000). Antagonist to P2X4, P2X7 and P2Y₁₂ receptors on microglia have been shown to reduce neuropathic and inflammatory pain (Burnstock, 2009; Inoue, 2007). There is increasing attention to the potential roles of purinergic signalling in trauma, ischaemia and neurodegenerative conditions, including Alzheimer’s, Parkinson’s and Huntington’s diseases, multiple sclerosis and amyotrophic lateral sclerosis (Burnstock, 2007; Sperlágh and Illes, 2014). The involvement of purinergic signalling in epilepsy, neuropsychiatric diseases and mood disorders has also been reported (Boisson and Burnstock, 2010; Burnstock, 2008b).

Purinergic agents are being investigated for the treatment of disorders of the urinary tract (Burnstock, 2011), skeletal muscle (Ryten et al., 2004), gut (Burnstock, 2008a), bone (Burnstock and Arnett, 2006; Orriss et al., 2010), the cardiovascular system (Erlinge and Burnstock, 2008), kidney (Bailey et al., 2007; Taylor et al., 2009) and the reproductive system (Calvert et al., 2008; Gür et al., 2009). There are also reports that extracellular ATP acts on P2Y₂ receptors to facilitate HIV-1 infection (e.g. Séror et al., 2011). The therapeutic potential of purinergic compounds for the treatment of cancer is being explored (Burnstock and Di Virgilio, 2013; Shabbir and Burnstock, 2009; Shabbir et al., 2008; Stagg and Smyth, 2010; White and Burnstock, 2006; White et al., 2009). Selective purinoceptor agonists and antagonists with therapeutic potential are also being developed for thrombosis and stroke, atherosclerosis, kidney failure, osteoporosis, bladder incontinence and colitis (Bartlett et al., 2014; Burnstock, 2006, 2013). This would be facilitated by the discovery of selective purinoceptor agonists and antagonists that are orally bioavailable and stable in vivo.

Footnotes

Declaration of conflicting interests

The author declared no potential conflicts of interest with respect to the research, authorship and/or publication of this article.

Funding

The author received no financial support for the research, authorship and/or publication of this article.

References

Abbracchio

Burnstock

(1994) Purinoceptors: Are there families of P2X and P2Y purinoceptors? Pharmacology & Therapeutics 64(3): 445–475.

Abbracchio

Burnstock

(1998) Purinergic signalling: Pathophysiological roles. Japanese Journal of Pharmacology 78(2): 113–145.

Abbracchio

Boeynaems

J-M

Barnard

et al . (2003) Characterization of the UDP-glucose receptor (re-named here the P2Y14 receptor) adds diversity to the P2Y receptor family. Trends in Pharmacological Sciences 24(2): 52–55.

Abbracchio

Burnstock

Boeynaems

J-M

et al . (2006) International Union of Pharmacology: Update on the P2Y G protein-coupled nucleotide receptors: From molecular mechanisms and pathophysiology to therapy. Pharmacological Reviews 58(3): 281–341.

Alves

da Silva

Ferreira

et al . (2014) Structural and molecular modeling features of P2X receptors. International Journal of Molecular Sciences 15(3): 4531–4549.

Bailey

Shirley

King

et al . (2007) Extracellular nucleotides and renal function. In: Alpern

RJ and

Herbert SCG (eds) The Kidney: Physiology and Pathophysiology (4th edn). San Diego, CA: Elsevier, pp. 425–443.

Bartlett

Stokes

Sluyter

(2014) The P2X7 receptor channel: Recent developments and the use of P2X7 antagonists in models of disease. Pharmacological Reviews 66(3): 638–675.

Schoepfer

Burnstock

(2000) Molecular cloning and characterization of a novel ATP P2X receptor subtype from embryonic chick skeletal muscle. Journal of Biological Chemistry 275(19): 14401–14407.

Zhang

Nassar

et al . (1995) A P2X purinoceptor cDNA conferring a novel pharmacological profile. FEBS Letters 375: 129–133.

10.

Bodin

Burnstock

(2001) Purinergic signalling: ATP release. Neurochemical Research 26(1-2): 959–969.

11.

Bogdanov

Dale

King

et al . (1997) Early expression of a novel nucleotide receptor in the neural plate of Xenopus Embryos. Journal of Biological Chemistry 272(19): 12583–12590.

12.

Bogdanov

Wildman

Clements

et al . (1998) Molecular cloning and characterization of rat P2Y4 nucleotide receptor (Special report). British Journal of Pharmacology 124(3): 428–430.

13.

Boisson

Burnstock

(eds) (2010) Purinergic signalling in epilepsy. The Open Neuroscience Journal 4: 23–113.

14.

Bradbury

Burnstock

McMahon

(1998) The expression of P2X3 purinoceptors in sensory neurons: Effects of axotomy and glial-derived neurotrophic factor. Molecular and Cellular Neurosciences 12(4-5): 256–268.

15.

Brake

Wagenbach

Julius

(1994) New structural motif for ligand-gated ion channels defined by an ionotropic ATP receptor. Nature 371(6497): 519–523.

16.

Brown

Filippov

Barnard

(2000) Inhibition of potassium and calcium currents in neurones by molecularly-defined P2Y receptors. Journal of the Autonomic Nervous System 81: 31–36.

17.

Brown

Townsend-Nicholson

Jacobson

et al . (2002) Heteromultimeric P2X1/2 receptors show a novel sensitivity to extracellular pH. Journal of Pharmacology and Experimental Therapeutics 300(2): 673–680.

18.

Buell

Collo

Rassendren

(1996) P2X receptors: An emerging channel family. European Journal of Neuroscience 8(10): 2221–2228.

19.

Burnstock

(1972) Purinergic nerves. Pharmacological Reviews 24(3): 509–581.

20.

Burnstock

(1976) Purinergic receptors. Journal of Theoretical Biology 62(2): 491–503.

21.

Burnstock

(1978) A basis for distinguishing two types of purinergic receptor. In: Straub

Bolis

(eds) Cell Membrane Receptors for Drugs and Hormones: A Multidisciplinary Approach. New York: Raven Press, pp. 107–118.

22.

Burnstock

(1996) A unifying purinergic hypothesis for the initiation of pain. Lancet 347(9015): 1604–1605.

23.

Burnstock

(1999) Release of vasoactive substances from endothelial cells by shear stress and purinergic mechanosensory transduction. Journal of Anatomy 194(3): 335–342.

24.

Burnstock

(2001) Purinergic signalling in lower urinary tract. In: Abbracchio

Williams

(eds) Handbook of Experimental Pharmacology: Purinergic and Pyrimidinergic Signalling I – Molecular, Nervous and Urinogenitary System Function, vol. 151/I. Berlin: Springer-Verlag, pp. 423–515.

25.

Burnstock

(2002) Purinergic signalling and vascular cell proliferation and death. Arteriosclerosis, Thrombosis, and Vascular Biology 22(3): 364–373.

26.

Burnstock

(2003) Introduction: ATP and its metabolites as potent extracellular agonists. In: Schwiebert

(ed.) Current Topics in Membranes: Purinergic Receptors and Signalling, vol. 54. San Diego, CA: Academic Press, pp. 1–27.

27.

Burnstock

(2006) Pathophysiology and therapeutic potential of purinergic signaling. Pharmacological Reviews 58(1): 58–86.

28.

Burnstock

(2007) Physiology and pathophysiology of purinergic neurotransmission. Physiological Reviews 87(2): 659–797.

29.

Burnstock

(2008a) Commentary: Purinergic receptors as future targets for treatment of functional GI disorders. Gut 57(9): 1193–1194.

30.

Burnstock

(2008b) Purinergic signalling and disorders of the central nervous system. Nature Reviews Drug Discovery 7(7): 575–590.

31.

Burnstock

(2009) Purinergic receptors and pain. Current Pharmaceutical Design 15(15): 1717–1735.

32.

Burnstock

(2011) Therapeutic potential of purinergic signalling for diseases of the urinary tract. BJU International 107(2): 192–204.

33.

Burnstock

(2012) Purinergic signalling: Its unpopular beginning, its acceptance and its exciting future. Bioessays 34(3): 218–225.

34.

Burnstock

(2013) Purinergic mechanisms and pain – An update. European Journal of Pharmacology 716(1-3): 24–40.

35.

Burnstock

(2014) Cotransmission. In: Caplan

(ed.). Reference Module in Biomedical Sciences. Oxford: Elsevier, pp. 1–8.

36.

Burnstock

Arnett

(2006) Edited Monograph: Nucleotides and Regulation of Bone Cell Function. Boca Raton, FL: Taylor & Francis Group.

37.

Burnstock

Di Virgilio

(2013) Purinergic signalling in cancer. Purinergic Signalling 9(4): 491–540.

38.

Burnstock

Kennedy

(1985) Is there a basis for distinguishing two types of P2-purinoceptor? General Pharmacology 16(5): 433–440.

39.

Burnstock

Knight

(2004) Cellular distribution and functions of P2 receptor subtypes in different systems. International Review of Cytology 240: 31–304.

40.

Burnstock

Ulrich

(2011) Purinergic signalling in embryonic and stem cell development. Cellular and Molecular Life Sciences 68(8): 1369–1394.

41.

Burnstock

Verkhratsky

(2010) Long-term (trophic) purinergic signalling: Purinoceptors control cell proliferation, differentiation and death. Cell Death & Disease 1: e9.

42.

Burnstock

Cocks

Kasakov

et al . (1978) Direct evidence for ATP release from non-adrenergic, non-cholinergic (‘purinergic’) nerves in the guinea-pig taenia coli and bladder. European Journal of Pharmacology 49(2): 145–149.

43.

Burnstock

Krügel

Abbracchio

et al . (2011) Purinergic signalling: From normal behaviour to pathological brain function. Progress in Neurobiology 95(2): 229–274.

44.

Calvert

Evans

(2004) Heterogeneity of P2X receptors in sympathetic neurons: Contribution of neuronal P2X1 receptors revealed using knockout mice. Molecular Pharmacology 65(1): 139–148.

45.

Calvert

Khan

Thompson

et al . (2008) A functional study of purinergic signalling in the normal and pathological rabbit corpus cavernosum. BJU International 101(8): 1043–1047.

46.

Caseley

Muench

Roger

et al . (2014) Non-synonymous single nucleotide polymorphisms in the P2X receptor genes: Association with diseases, impact on receptor functions and potential use as diagnosis biomarkers. International Journal of Molecular Sciences 15(8): 13344–13371.

47.

Chambers

Macdonald

Sarau

et al . (2000) A G protein-coupled receptor for UDP-glucose. Journal of Biological Chemistry 275(15): 10767–10771.

48.

Chen

Akopian

Sivilotti

et al . (1995) A P2X purinoceptor expressed by a subset of sensory neurons. Nature 377(6548): 428–431.

49.

Cockayne

Hamilton

Zhu

Q-M

et al . (2000) Urinary bladder hyporeflexia and reduced pain-related behaviour in P2X3-deficient mice. Nature 407(6807): 1011–1015.

50.

Communi

Gonzalez

Detheux

et al . (2001a) Identification of a novel human ADP receptor coupled to Gi. Journal of Biological Chemistry 276(44): 41479–41485.

51.

Communi

Robaye

Boeynaems

J-M

(2004) Nucleotide receptor P2Y4. Afcs-Nature Molecule Pages, ID A 001691.

52.

Communi

Suarez-Huerta

Dussossoy

et al . (2001b) Cotranscription and intergenic splicing of human P2Y11 and SSF1 genes. Journal of Biological Chemistry 276(19): 16561–16566.

53.

Compan

Ulmann

Stelmashenko

et al . (2012) P2X2 and P2X5 subunits define a new heteromeric receptor with P2X7-like properties. Journal of Neuroscience 32(12): 4284–4296.

54.

Cressman

Lazarowski

Homolya

et al . (1999) Effect of loss of P2Y2 receptor gene expression on nucleotide regulation of murine epithelial Cl-transport. Journal of Biological Chemistry 274(37): 26461–26468.

55.

Delic

Zimmermann

(2010) Nucleotides affect neurogenesis and dopaminergic differentiation of mouse fetal midbrain-derived neural precursor cells. Purinergic Signalling 6(4): 417–428.

56.

Drury

Szent-Györgyi

(1929) The physiological activity of adenine compounds with special reference to their action upon the mammalian heart. Journal of Physiology 68(3): 213–237.

57.

Egan

Cox

Voigt

(2000) Molecular cloning and functional characterization of the zebrafish ATP-gated ionotropic receptor P2X3 subunit. FEBS Letters 475(3): 287–290.

58.

Erlinge

Burnstock

(2008) P2 receptors in cardiovascular physiology and disease. Purinergic Signalling 4(1): 1–20.

59.

Fredholm

IJzerman

Jacobson

et al . (2001) International union of pharmacology. XXV: Nomenclature and classification of adenosine receptors. Pharmacological Reviews 53(4): 527–552.

60.

Fumagalli

Trincavelli

Lecca

et al . (2004) Cloning, pharmacological characterisation and distribution of the rat G-protein-coupled P2Y13 receptor. Biochemical Pharmacology 68(1): 113–124.

61.

Garcia-Guzman

Soto

Laube

et al . (1996) Molecular cloning and functional expression of a novel rat heart P2X purinoceptor. FEBS Letters 388(2-3): 123–127.

62.

Garcia-Guzman

Stühmer

Soto

(1997) Molecular characterization and pharmacological properties of the human P2X3 purinoceptor. Brain Research, Molecular Brain Research 47(1-2): 59–66.

63.

Gür

Kadowitz

Abdel-Mageed

et al . (2009) Management of erectile function by purinergic P2 receptors in diabetic rat. Journal of Urology 181(2374): 2375–2382.

64.

Harden

(2004) Nucleotide receptor P2Y14. Afcs-Nature Molecule Pages ID A 002814.

65.

Hoebertz

Mahendran

Burnstock

et al . (2002) ATP and UTP at low concentrations strongly inhibit bone formation by osteoblasts: A novel role for the P2Y2 receptor in bone remodelling. Journal of Cellular Biochemistry 86(3): 413–419.

66.

Hollopeter

Jantzen

H-M

Vincent

et al . (2001) Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 409: 202–207.

67.

Hou

Moller

Edvinsson

et al . (2000) Cytokines induce upregulation of vascular P2Y2 receptors and increased mitogenic responses to UTP and ATP. Arteriosclerosis, Thrombosis and Vascular Biology 20(9): 2064–2069.

68.

Inoue

(2007) P2 receptors and chronic pain. Purinergic Signalling 3(1-2): 135–144.

69.

Kawate

Michel

Birdsong

et al . (2009) Crystal structure of the ATP-gated P2X4 ion channel in the closed state. Nature 460(7255): 592–598.

70.

Kellerman

Evans

Mathews

et al . (2002) Inhaled P2Y2 receptor agonists as a treatment for patients with cystic fibrosis lung disease. Advanced Drug Delivery Reviews 54(11): 1463–1474.

71.

Khakh

Proctor

Dunwiddie

et al . (1999) Allosteric control of gating and kinetics at P2X4 receptor channels. Journal of Neuroscience 19(17): 7289–7299.

72.

King

Townsend-Nicholson

Wildman

et al . (2000) Coexpression of rat P2X2 and P2X6 subunits in Xenopus oocytes. Journal of Neuroscience 20(13): 4871–4877.

73.

Kumral

Tuzun

Yesilirmak

et al . (2012) Genetic basis of apnoea of prematurity and caffeine treatment response: Role of adenosine receptor polymorphisms: Genetic basis of apnoea of prematurity. Acta Paediatrica 101(7): e299–e303.

74.

Läer

Vennemann

Rothämel

et al . (2013) Association between polymorphisms in the P2RY1 and SSTR2 genes and sudden infant death syndrome. International Journal of Legal Medicine 127(6): 1087–1091.

75.

Lazarowski

Rochelle

O’Neal

et al . (2001) Cloning and functional characterization of two murine uridine nucleotide receptors reveal a potential target for correcting ion transport deficiency in cystic fibrosis gallbladder. Journal of Pharmacology and Experimental Therapeutics 297(1): 43–49.

76.

Lazarowski

Sesma

Seminario-Vidal

et al . (2011) Molecular mechanisms of purine and pyrimidine nucleotide release. Advances in Pharmacology 61: 221–261.

77.

Ledent

Vaugeois

Schiffmann

et al . (1997) Aggressiveness, hypoalgesia and high blood pressure in mice lacking the adenosine A2a receptor. Nature 388(6643): 674–678.

78.

Léon

Vial

Cazenave

et al . (1996) Cloning and sequencing of a human cDNA encoding endothelial P2Y1 purinoceptor. Gene 171(2): 295–297.

79.

Lev

Patel

Guthikonda

et al . (2007) Genetic polymorphisms of the platelet receptors P2Y12, P2Y1 and GP IIIa and response to aspirin and clopidogrel. Thrombosis Research 119(3): 355–360.

80.

Lewis

Neidhart

Holy

et al . (1995) Coexpression of P2X2 and P2X3 receptor subunits can account for ATP-gated currents in sensory neurons. Nature 377(6548): 432–435.

81.

Libert

Parmentier

Lefort

et al . (1989) Selective amplification and cloning of four new members of the G protein-coupled receptor family. Science 244(4904): 569–572.

82.

Londos

Cooper

Wolff

(1980) Subclasses of external adenosine receptors. Proceedings of the National Academy of Sciences of the United States of America 77(5): 2551–2554.

83.

Lustig

Shiau

Brake

et al . (1993) Expression cloning of an ATP receptor from mouse neuroblastoma cells. Proceedings of the National Academy of Sciences of the United States of America 90(11): 5113–5117.

84.

Lynch

Touma

Niforatos

et al . (1999) Molecular and functional characterization of human P2X2 receptors. Molecular Pharmacology 56(6): 1171–1181.

85.

Moore

Iritani

Chambers

et al . (2000) Immunohistochemical localization of the P2Y1 purinergic receptor in Alzheimer’s disease. Neuroreport 11(17): 3799–3803.

86.

Nicke

Baumert

Rettinger

et al . (1998) P2X1 and P2X3 receptors form stable trimers: A novel structural motif of ligand-gated ion channels. EMBO Journal 17(11): 3016–3028.

87.

Nicke

Kerschensteiner

Soto

(2005) Biochemical and functional evidence for heteromeric assembly of P2X1 and P2X4 subunits. Journal of Neurochemistry 92(4): 925–933.

88.

North

(2002) Molecular physiology of P2X receptors. Physiological Reviews 82(4): 1013–1067.

89.

Orriss

Burnstock

Arnett

(2010) Purinergic signalling and bone remodelling. Current Opinion in Pharmacology 10(3): 322–330.

90.

Parravicini

Ranghino

Abbracchio

et al . (2008) GPR17: Molecular modeling and dynamics studies of the 3-D structure and purinergic ligand binding features in comparison with P2Y receptors. BMC Bioinformatics 9: 263.

91.

Ralevic

Burnstock

(1998) Receptors for purines and pyrimidines. Pharmacological Reviews 50(3): 413–492.

92.

Reshkin

Guerra

Bagorda

et al . (2000) Activation of A3 adenosine receptor induces calcium entry and chloride secretion in A6 cells. Journal of Membrane Biology 178(2): 103–113.

93.

Robaye

Ghanem

Wilkin

et al . (2003) Loss of nucleotide regulation of epithelial chloride transport in the jejunum of P2Y4-null mice. Molecular Pharmacology 63(4): 777–783.

94.

Roberts

Vial

Digby

et al . (2006) Molecular properties of P2X receptors. Pflugers Arch: European Journal of Physiology 452(5): 486–500.

95.

Rokic

Stojilkovic

(2013) Two open states of P2X receptor channels. Frontiers in Cellular Neuroscience 7: 215.

96.

Rong

Burnstock

(2004) Activation of ureter nociceptors by exogenous and endogenous ATP in guinea pig. Neuropharmacology 47(7): 1093–1101.

97.

Ryten

Yang

Dunn

et al . (2004) Purinoceptor expression in regenerating skeletal muscle in the mdx mouse model of muscular dystrophy and in satellite cell cultures. FASEB Journal 18(12):1404–1406.

98.

Savi

Herbert

(2005) Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis. Seminars in Thrombosis and Hemostasis 31(2): 174–183.

99.

Séror

Melki

Subra

et al . (2011) Extracellular ATP acts on P2Y2 purinergic receptors to facilitate HIV-1 infection. Journal of Experimental Medicine 208(9): 1823–1834.

100.

Shabbir

Burnstock

(2009) Purinergic receptor-mediated effects of adenosine 5’-triphosphate in urological malignant diseases. International Journal of Urology 16(2): 143–150.

101.

Shabbir

Thompson

Jarmulowicz

et al . (2008) Effect of extracellular ATP on the growth of hormone refractory prostate cancer in vivo. BJU International 102(1): 108–112.

102.

Shen

Seye

Wang

et al . (2004) Cloning, up-regulation, and mitogenic role of porcine P2Y2 receptor in coronary artery smooth muscle cells. Molecular Pharmacology 66(5): 1265–1274.

103.

Soto

Garcia-Guzman

Karschin

et al . (1996) Cloning and tissue distribution of a novel P2X receptor from rat brain. Biochemical and Biophysical Research Communication 223(2): 456–460.

104.

Spelta

Mekhalfia

Rejman

et al . (2003) ATP analogues with modified phosphate chains and their selectivity for rat P2X2 and P2X2/3 receptors. British Journal of Pharmacology 140(6): 1027–1034.

105.

Sperlágh

Illes

(2014) P2X7 receptor: An emerging target in central nervous system diseases. Trends in Pharmacological Sciences 35(10): 537–547.

106.

Stagg

Smyth

(2010) Extracellular adenosine triphosphate and adenosine in cancer. Oncogene 29(39): 5346–5358.

107.

Stelmashenko

Lalo

Yang

et al . (2012) Activation of trimeric P2X2 receptors by fewer than three ATP molecules. Molecular Pharmacology 82(4): 760–766.

108.

Stojilkovic

Tomic

et al . (2005) Molecular dissection of purinergic P2X receptor channels. Annals of the New York Academy of Sciences 1048(1): 116–130.

109.

Sun

Samuelson

Yang

et al . (2001) Mediation of tubuloglomerular feedback by adenosine: Evidence from mice lacking adenosine 1 receptors. Proceedings of the National Academy of Sciences of the United States of America 98(17): 9983–9988.

110.

Surprenant

Rassendren

Kawashima

et al . (1996) The cytolytic P2Z receptor for extracellular ATP identified as a P2X receptor (P2X7). Science 272(5262): 735–738.

111.

Surprenant

Schneider

Wilson

et al . (2000) Functional properties of heteromeric P2X1/5 receptors expressed in HEK cells and excitatory junction potentials in guinea-pig submucosal arterioles. Journal of the Autonomic Nervous System 81(1-3): 249–263.

112.

Taylor

SRJ

Turner

Elliott

et al . (2009) P2X7-deficiency ameliorates accelerated nephrotoxic nephritis in mice. Journal of the American Society of Nephrology 20(6): 1275–1281.

113.

Tian

Abdelrahman

Weinhausen

et al . (2014) Carbamazepine derivatives with P2X4 receptor-blocking activity. Bioorganic & Medicinal Chemistry 22(3): 1077–1088.

114.

Torres

Egan

Voigt

(1999) Hetero-oligomeric assembly of P2X receptor subunits. Specificities exist with regard to possible partners. Journal of Biological Chemistry 274(10): 6653–6659.

115.

Trujillo

Schwindt

Martins

et al . (2009) Novel perspectives of neural stem cell differentiation: From neurotransmitters to therapeutics. Cytometry A 75(1): 38–53.

116.

Valera

Hussy

Evans

et al . (1994) A new class of ligand-gated ion channel defined by P2X receptor for extra-cellular ATP. Nature 371(6497): 516–519.

117.

Van Calker

Müller

Hamprecht

(1979) Adenosine regulates via two different types of receptors, the accumulation of cyclic AMP in cultured brain cells. Journal of Neurochemistry 33(5): 999–1005.

118.

Vassort

(2001) Adenosine 5’-triphosphate: A P2-purinergic agonist in the myocardium. Physiological Reviews 81(2): 767–806.

119.

Verkhratsky

Burnstock

(2014) Biology of purinergic signalling: Its ancient evolutionary roots, its omnipresence and its multiple functional significance. BioEssays 36 (7): 697–705.

120.

Vidal

Hicks

Langer

(1986) Differential effects of alpha-beta-methylene ATP on responses to nerve stimulation in SHR and WKY tail arteries. Naunyn-Schmiedebergs Archives of Pharmacology 332(4): 384–390.

121.

Vlaskovska

Kasakov

Rong

et al . (2001) P2X3 knock-out mice reveal a major sensory role for urothelially released ATP. Journal of Neuroscience 21(15): 5670–5677.

122.

Webb

Simon

Krishek

et al . (1993) Cloning and functional expression of a brain G-protein-coupled ATP receptor. FEBS Letters 324(2): 219–225.

123.

Wesselius

Bours

Henriksen

et al . (2013) Association of P2Y2 receptor SNPs with bone mineral density and osteoporosis risk in a cohort of Dutch fracture patients. Purinergic Signalling 9(1): 41–49.

124.

White

Burnstock

(2006) P2 receptors and cancer. Trends in Pharmacological Sciences 27(4): 211–217.

125.

White

Knight

Butler

PEM

et al . (2009). An in vivo model of melanoma: Treatment with ATP. Purinergic Signalling 5(3): 327–333.

126.

Wynn

Burnstock

(2006) Adenosine 5’-triphosphate and its relationship with other mediators that activate pelvic afferent neurons in the rat colorectum. Purinergic Signalling 2(3): 517–526.

127.

Yegutkin

(2008) Nucleotide- and nucleoside-converting ectoenzymes: Important modulators of purinergic signalling cascade. Biochimica Etbiophysica Acta 1783(5): 673–694.

128.

Yoshioka

Hosoda

Kuroda

et al . (2002) Hetero-oligomerization of adenosine A1 receptors with P2Y1 receptors in rat brains. FEBS Letters 531(2): 299–303.

129.

Zhou

Olah

et al . (1992) Molecular cloning and characterization of an adenosine receptor: The A3 adenosine receptor. Proceedings of the National Academy of Sciences of the United States of America 89(16): 7432–7436.

130.

Zimmermann

Mishra

Shukla

et al . (2007) Ecto-nucleotidases, molecular properties and functional impact. Anales de la Real Academia Nacional de Farmacia 73: 537–566.

Purine and purinergic receptors

Abstract

Keywords

Introduction

P1 receptors

P2X receptors

P2X receptor subtypes

P2Y receptors

P2Y receptor subtypes

Physiology of purinergic signalling

Purinergic pathophysiology and therapeutic potential

Footnotes

Declaration of conflicting interests

Funding

References